Pursuing first-in-class targeted therapies

The PI3K/mTOR pathway has been implicated in breast, prostate, endometrial, ovarian and hematological cancers, among others.

We are currently developing our lead drug candidate, gedatolisib, in metastatic breast cancer.

Therapeutic Pipeline: Gedatolisib

The PI3K – mTOR Pathway

How and why we target the PI3K and mTOR pathway in cancer

Gedatolisib

Internal development of a pan-PI3K/mTOR inhibitor

Companion Diagnostic Pipeline: CELsignia

We are using our CELsignia platform to expand new indications for already approved targeted therapies.